BSE: 530057
Vivanza Biosciences Limited
Operates across three reported business areas: Pharmaceuticals, Agro, and Plastic polymer films, with consolidated FY26 revenue of Rs. 115.91 crore and a net profit of Rs. 0.39 crore. The June 2026 filings disclose a non-binding strategic cooperation and technology transfer agreement to set up a plastic film manufacturing project in the Kyrgyz Republic, covering technology transfer, machinery sourcing, government liaison, investment facilitation, skill development, import-export support, and financing assistance; no monetary consideration has been recorded and a joint venture is only contemplated later. The cost shape is unusual for a manufacturer: materials are shown as 0.0% of revenue, with employee cost at 0.4% and other operating expenses at 0.2% of revenue, suggesting the reported revenue is largely a pass-through or trading activity rather than in-house manufacturing. Operating cash flow on a standalone basis was negative Rs. 121.35 Lacs in FY26, even as the company moved from a loss of Rs. 69.51 Lacs in FY25 to a profit of Rs. 37.50 Lacs on a standalone revenue jump from Rs. 294.28 Lacs to Rs. 11,223.10 Lacs. The company is a micro-cap BSE-listed entity (paid-up equity Rs. 4 crore, net worth Rs. 4.02 crore) headquartered in Ahmedabad, with two promoters holding shares and no encumbrance declared on them. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceuticals, Agro, Plastic polymer films. Small, multi-segment micro-cap with a trading-style cost structure and a cross-border plastic film project in early, non-binding stage.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 10 | 18 | 28 | 7 | 116 |
| EBITDA (ex other income) | (0) | 1 | 1 | (0) | 1 |
| margin % | (0.8) | 3.7 | 3.8 | (4.9) | 0.6 |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 0.83 | 1.50 | 0.14 | 0.17 | 0.10 |
| ROE % · ROCE % | 9.5 · 12.1 | 14.6 · 20.5 | 11.8 · 15.1 | (17.0) · (4.3) | 9.0 · 15.7 |
| Debt / equity (x) | 0.79 | 1.95 | 1.11 | 2.18 | 2.34 |
| Cash from operations | 2 | (1) | 2 | (2) | (1) |
| Capex | 0 | 0 | (0) | (0) | (0) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 2 | 0 | 9 | 55 | 45 | 6 | 9 |
| Profit before tax | 0 | 0 | (1) | 0 | 1 | 0 | (0) | 0 |
| Net profit | 0 | 0 | (1) | 0 | 1 | 0 | (0) | 0 |
| EPS (₹) | 0.00 | 0.01 | 0.25 | 0.02 | 0.14 | 0.05 | 0.11 | 0.04 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 4.4 | 30.8 | 6 of 158 | 97% |
| P/B | 1.4 | 3.1 | 37 of 163 | 77% |
| ROCE | 10.4 | 10.8 | 95 of 183 | 48% |
| ROE | 9.1 | 9.8 | 91 of 166 | 46% |
| Debt / Equity | 2.3 | 0.2 | 163 of 166 | 2% |
| EBITDA margin | 3.2 | 17.5 | 147 of 165 | 11% |
| Revenue growth | 3.9 | 16.3 | 117 of 161 | 28% |
| Profit growth | 68.7 | 30.9 | 50 of 158 | 69% |
| Market cap | 6 | 806 | 178 of 181 | 2% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 28 Oct 2026 · Board to approve September 2026 quarterly and half-year results | results | low | — | — |
| 8 Oct 2026 · Statement of Deviation not applicable as no fresh funds raised | compliance | minimal | — | — |
| 2 Oct 2026 · Routine compliance certificate for Q2 FY27 dematerialization | compliance | minimal | — | — |
| 28 Sept 2026 · Trading Window Closure from 1 Oct 2026 ahead of Q2 FY26 Results | compliance | minimal | — | — |
| 12 Sept 2026 · Vivanza Biosciences 44th AGM: All 9 resolutions passed | board shareholder meetings | low | — | — |
| 12 Sept 2026 · Revised AGM outcome filed - corrigendum to correct e-voting provider name | board shareholder meetings | medium | — | — |
| 11 Sept 2026 · 44th AGM outcome: 9 items put to e-vote, results awaited | board shareholder meetings | low | — | — |
| 20 Aug 2026 · Notice of 44th AGM and e-voting info published in newspapers | compliance | minimal | — | — |
| 19 Aug 2026 · Notice of 44th AGM and Annual Report for FY 2025-26 | board shareholder meetings | medium | — | — |
| 19 Aug 2026 · 44th AGM notice on September 11, 2026 via video conference | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.